BNC 210

Drug Profile

BNC 210

Alternative Names: BNC210; IW 2143

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionomics
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Agitation
  • Suspended Anxiety disorders; Post-traumatic stress disorders
  • No development reported Depressive disorders

Most Recent Events

  • 02 Oct 2018 Suspended - Phase-II for Post-traumatic stress disorder in USA and Australia following failure to meet primary endpoint (PO)
  • 19 Jul 2018 Bionomics plans a clinical trial for Anxiety disorders and post-traumatic stress disorder in Australia (In volunteers) (ACTRN12618001197224)
  • 24 May 2018 Phase-II clinical trials in Agitation (In the elderly) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top